Cargando…
Lymph node evaluation in endometrial cancer: how did it change over the last two decades?
Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, and surgery represents the pivotal part of treatment. Hysterectomy and salpingo-oophorectomy allow removing the primary tumor and defining patients at higher risk, who might benefit from adjuvant therapies. M...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799029/ https://www.ncbi.nlm.nih.gov/pubmed/35117380 http://dx.doi.org/10.21037/tcr-20-2165 |
_version_ | 1784641967896920064 |
---|---|
author | Pinelli, Ciro Artuso, Valeria Bogani, Giorgio Laganà, Antonio Simone Ghezzi, Fabio Casarin, Jvan |
author_facet | Pinelli, Ciro Artuso, Valeria Bogani, Giorgio Laganà, Antonio Simone Ghezzi, Fabio Casarin, Jvan |
author_sort | Pinelli, Ciro |
collection | PubMed |
description | Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, and surgery represents the pivotal part of treatment. Hysterectomy and salpingo-oophorectomy allow removing the primary tumor and defining patients at higher risk, who might benefit from adjuvant therapies. Minimally invasive surgery is associated with superior postoperative outcomes and represents a safe and effective approach for surgical staging of EC. The lymph node status evaluation in EC is still a matter of debate. Over the last twenty years much has changed, moving from a full systematic pelvic and paraaortic lymphadenectomy for staging purpose to the removal of the pelvic (with or without paraaortic) lymph nodes only in selected EC classes of risk. Two randomized trials failed to demonstrate survival benefits of lymphadenectomy in case of apparent early stage EC; however, its prognostic role has never been questioned. At present, with the aim of reducing the surgical-related morbidity, sentinel node mapping is emerging as a safe and valid alternative to lymphadenectomy for EC staging, demonstrating high accuracy and an increased detection of lymph nodes metastasis. Here, we performed a review of the most significant studies, which supported the changes in the lymph node status evaluation for EC over the last two decades. |
format | Online Article Text |
id | pubmed-8799029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87990292022-02-02 Lymph node evaluation in endometrial cancer: how did it change over the last two decades? Pinelli, Ciro Artuso, Valeria Bogani, Giorgio Laganà, Antonio Simone Ghezzi, Fabio Casarin, Jvan Transl Cancer Res Review Article on Endometrial Cancer Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, and surgery represents the pivotal part of treatment. Hysterectomy and salpingo-oophorectomy allow removing the primary tumor and defining patients at higher risk, who might benefit from adjuvant therapies. Minimally invasive surgery is associated with superior postoperative outcomes and represents a safe and effective approach for surgical staging of EC. The lymph node status evaluation in EC is still a matter of debate. Over the last twenty years much has changed, moving from a full systematic pelvic and paraaortic lymphadenectomy for staging purpose to the removal of the pelvic (with or without paraaortic) lymph nodes only in selected EC classes of risk. Two randomized trials failed to demonstrate survival benefits of lymphadenectomy in case of apparent early stage EC; however, its prognostic role has never been questioned. At present, with the aim of reducing the surgical-related morbidity, sentinel node mapping is emerging as a safe and valid alternative to lymphadenectomy for EC staging, demonstrating high accuracy and an increased detection of lymph nodes metastasis. Here, we performed a review of the most significant studies, which supported the changes in the lymph node status evaluation for EC over the last two decades. AME Publishing Company 2020-12 /pmc/articles/PMC8799029/ /pubmed/35117380 http://dx.doi.org/10.21037/tcr-20-2165 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Review Article on Endometrial Cancer Pinelli, Ciro Artuso, Valeria Bogani, Giorgio Laganà, Antonio Simone Ghezzi, Fabio Casarin, Jvan Lymph node evaluation in endometrial cancer: how did it change over the last two decades? |
title | Lymph node evaluation in endometrial cancer: how did it change over the last two decades? |
title_full | Lymph node evaluation in endometrial cancer: how did it change over the last two decades? |
title_fullStr | Lymph node evaluation in endometrial cancer: how did it change over the last two decades? |
title_full_unstemmed | Lymph node evaluation in endometrial cancer: how did it change over the last two decades? |
title_short | Lymph node evaluation in endometrial cancer: how did it change over the last two decades? |
title_sort | lymph node evaluation in endometrial cancer: how did it change over the last two decades? |
topic | Review Article on Endometrial Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799029/ https://www.ncbi.nlm.nih.gov/pubmed/35117380 http://dx.doi.org/10.21037/tcr-20-2165 |
work_keys_str_mv | AT pinelliciro lymphnodeevaluationinendometrialcancerhowdiditchangeoverthelasttwodecades AT artusovaleria lymphnodeevaluationinendometrialcancerhowdiditchangeoverthelasttwodecades AT boganigiorgio lymphnodeevaluationinendometrialcancerhowdiditchangeoverthelasttwodecades AT laganaantoniosimone lymphnodeevaluationinendometrialcancerhowdiditchangeoverthelasttwodecades AT ghezzifabio lymphnodeevaluationinendometrialcancerhowdiditchangeoverthelasttwodecades AT casarinjvan lymphnodeevaluationinendometrialcancerhowdiditchangeoverthelasttwodecades |